XML 49 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1
DEFERRED REVENUE, REFUND LIABILITY AND LIABILITY RELATED TO SALE OF FUTURE ROYALTIES (Tables)
 6 Months Ended
Jun. 30, 2024
Other Liabilities Disclosure [Abstract]  
Summary of Deferred Revenue Balances
The Company had the following deferred revenue balances as of June 30, 2024 (in thousands):
 June 30, 2024
Deferred Revenue:Short-TermLong-TermTotal
CSL Vifor License Agreement$43,296 — $43,296 
Total$43,296 $— $43,296 
The following tables present changes in the Company’s contract assets and liabilities related to license and other revenue (in thousands):
Six Months Ended June 30, 2024
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract asset:    
Accounts receivable(1)
$3,333 $4,037 $(5,542)$1,828 
Contract liability:
Deferred revenue$43,296 $695 $(695)$43,296 
Six Months Ended June 30, 2023
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract assets:
Accounts receivable(1)
$1,901 $943 $(2,319)$525 
Prepaid expenses and other current assets$781 $— $(781)$— 
Contract liabilities:
Deferred revenue$47,034 $— $(3,738)$43,296 
 (1) Excludes accounts receivable related to amounts due to the Company from product sales of Auryxia which are included in the accompanying unaudited condensed consolidated balance sheets as of June 30, 2024 and 2023.
Liability Related to Sale of Future Royalties As of June 30, 2024 and December 31, 2023 the balances were as follows (in thousands):                        
Liability related to sale of future royaltiesJune 30, 2024December 31, 2023
Current portion (included in accrued expenses and other current liabilities)$2,013 $2,048 
Long-term portion53,101 54,013 
Total liability related to sale of future royalties$55,114 $56,061